- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05709730
Follow-up of Cell Changes in the Cervix
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The aim of the study is to clarify whether follow-up of cell changes is carried out with sufficiently good quality. It is nationally recommended to perform an HPV test on mild cell changes and only refer to clinical follow-up if you are HPV positive. Descriptive statistics on HPV-testing and follow-up of quality are not available today. If HPV testing has not already been performed, archived samples with glandular cell changes will be HPV-analyzed in Cobas 4800 HPV-polymerase chain reaction (PCR), which shows data on the presence of HPV and Luminex-PCR, which shows which HPV types the samples have. Women with low-grade squamous cell changes (ASCUS and CIN1) with simultaneous HPV analysis will be followed up with data from the Swedish National Cervical Screening Registry (NKCx) from the last ten years. A register linkage with data from NKCx and the National Cancer Registry at the National Board of Health and Welfare will be carried out to determine which women have developed gynecological cancer, cervical cancer and/or pre-cancer (cancer in situ). A follow-up review of reported original cytological (cell samples) and histological (tissue samples) diagnoses will be performed by cytodiagnostics and cytopathologists, to verify the correct diagnosis.
Statistics on collection of non-organized cell samples after a partial negative sample where follow-up is not recommended are produced in aggregated form in the form of an extract from NKCx
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Stockholm, Sweden, 14186
- Karolinska University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- women with an AGC diagnosis between February 17, 2014 and December 31, 2018
- 23-80 years old
- resident of the Stockholm-Gotland region of Sweden
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Women aged 26-80 with atypical glandular cell (AGC) cytology result
Women in the capital region of Sweden with AGC, a concomitant human papillomavirus (HPV) analysis, and a histopathology.
|
HPV genotyping of samples classified that were positive for "other HPV"
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
cervical intraepithelial neoplasia 3 (CIN3+)
Time Frame: 2014-2018
|
Risk for developing CIN3+ or worse depending on HPV type
|
2014-2018
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Joakim Dillner, MD PhD, Joakim Dillner. Professor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AGC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer of Cervix
-
Tata Memorial HospitalCompletedCervical Cancer | Cervix Cancer | Cancer of Cervix | Cancer of the CervixIndia
-
Duke UniversityWallace H. Coulter FoundationCompletedCancer of the Cervix, Cancer of the EndometriumUnited States
-
Eli Lilly and CompanyCompletedCancer of CervixMexico, Thailand, Argentina, Bosnia and Herzegovina, India, Pakistan, Peru
-
Newish Technology (Beijing) Co., Ltd.Recruiting
-
Tata Memorial HospitalCompleted
-
Women's Hospital School Of Medicine Zhejiang UniversityAkesoNot yet recruitingCervical Cancer | Uterine Cervical Neoplasms | Cancer of Cervix | Uterine Cervical Cancer | Cervical Neoplasms | Cancer of the Uterine Cervix
-
Banaras Hindu UniversityCompletedCervical Cancer | Cervix Cancer | Cancer of the Uterine CervixIndia
-
Bnai Zion Medical CenterUnknownInduction of Labor | Unfavorable CervixIsrael
-
Fatma Ahmed Abdelfatah RikabeSohag UniversityNot yet recruiting
-
Hillel Yaffe Medical CenterCompletedUnfavorable Cervix for Induction of LaborIsrael
Clinical Trials on HPV genotyping
-
Universitaire Ziekenhuizen KU LeuvenSciensanoTerminatedHuman Immunodeficiency VirusBelgium
-
Chang Gung Memorial HospitalDr. Chip Biotechnology IncorporationCompletedCervical Intraepithelial Neoplasia | HPV Infection | Human Papillomavirus InfectionTaiwan
-
Becton, Dickinson and CompanyActive, not recruiting
-
Materno-Perinatal Hospital of the State of MexicoUniversidad Autonoma del Estado de MexicoCompletedIntraepithelial Neoplasia
-
ANRS, Emerging Infectious DiseasesUniversity Hospital, Geneva; University of Bordeaux; International Agency for... and other collaboratorsRecruitingHIV Infections | HPV - Anogenital Human Papilloma Virus InfectionBurkina Faso, Cambodia, Côte D'Ivoire
-
Chulalongkorn UniversityCompletedPterygium | Human Papilloma Virus InfectionThailand
-
AeskuLab Pathology PragueInstitute of Biostatistics and analyses, Ltd.CompletedAlgorithm for Cervix Carcinoma ScreeningCzechia
-
University Hospital, RouenInstitut National de la Santé Et de la Recherche Médicale, FranceCompleted
-
Kyungpook National University HospitalCompletedAge-Related Macular DegenerationKorea, Republic of
-
Memorial Sloan Kettering Cancer CenterM.D. Anderson Cancer Center; Mayo Clinic; Dana-Farber Cancer Institute; Duke University and other collaboratorsActive, not recruitingLeukemiaUnited States